Jazz JZP-110 trial finalizes enrollment

Jazz Pharmaceuticals plc recently reported that enrollment for its two Phase 3 clinical trials for JZP-110 has been finalized.

The two studies will assess JZP-110 in excessive sleepiness (ES) that is linked with obstructive sleep apnea (OSA).

"We are pleased to have reached this important milestone in our Phase 3 program," Jazz Pharmaceuticals Global Head of Research and Development and CMO Dr. Karen Smith said. "We look forward to reporting the top-line results from the two OSA studies in the first quarter of 2017."

The total number of patients enrolled in the two trials is more than 654. Both of the clinical trials will assess the safety and effectiveness of JZP-110 when treating ES in adults who have OSA. The two trials will be double-blind, placebo-controlled and conducted over multiple centers.

The two trials have the same main goals of the Epworth Sleepiness Scale (ESS) and the Maintenance of Wakefulness Test (MWT). These goals have been authorized and are common in the use of clinical practices used to measure ES severity and patients' ability to stay awake.